Half of the respondents (50.9%) have a CD4 count of less than 500 cells/μL. Three hundred thirty-three (78.4%) of the participants were classified under the WHO clinical stage I and among the participants, 47 (11.1%) had history comorbidity called tuberculosis. This evidence concerns the gene CD4 and tuberculosis.